BRIEF—Chugai takes legal action to block Alexion candidate

Japan’s Chugai Pharmaceutical has filed a patent infringement lawsuit against Alexion Pharmaceuticals in the in the US District Court for Delaware.

Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) infringes one of its US patents, relating to its proprietary antibody engineering technology.

Chugai wants an injunction to stop Alexion from manufacturing and selling the candidate within the USA.